Compare AGIO & XHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AGIO | XHR |
|---|---|---|
| Founded | 2007 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | 2013 | N/A |
| Metric | AGIO | XHR |
|---|---|---|
| Price | $28.65 | $15.25 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 7 |
| Target Price | ★ $36.25 | $14.14 |
| AVG Volume (30 Days) | ★ 1.3M | 893.2K |
| Earning Date | 02-12-2026 | 02-24-2026 |
| Dividend Yield | N/A | ★ 3.66% |
| EPS Growth | N/A | ★ 139.32 |
| EPS | N/A | ★ 0.55 |
| Revenue | $44,791,000.00 | ★ $1,074,772,000.00 |
| Revenue This Year | $27.83 | $4.52 |
| Revenue Next Year | $134.79 | $3.13 |
| P/E Ratio | ★ N/A | $27.59 |
| Revenue Growth | ★ 36.26 | 4.29 |
| 52 Week Low | $22.24 | $8.55 |
| 52 Week High | $46.00 | $15.61 |
| Indicator | AGIO | XHR |
|---|---|---|
| Relative Strength Index (RSI) | 52.75 | 60.68 |
| Support Level | $26.25 | $14.37 |
| Resistance Level | $28.87 | $15.61 |
| Average True Range (ATR) | 1.09 | 0.41 |
| MACD | 0.25 | 0.02 |
| Stochastic Oscillator | 74.29 | 72.01 |
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
Xenia Hotels & Resorts Inc is a real estate investment trust that invests in premium full-service, lifestyle, and urban upscale hotels and resorts across the United States. The company owns and pursues hotels in the upscale, upper upscale, and luxury segments that are affiliated with various brands. Its hotels are operated by Marriott, along with Hilton, Hyatt, Starwood, Kimpton, Aston, Fairmont, and Loews. The firm's properties are located in various regions across the U.S.: the South Atlantic, West South Central, Pacific, Mountain, and other. Xenia's revenue is divided between room, food and beverage, and other. The firm's customer groups include transient business, group business, and contract business.